Intravenous glucose tolerance test and anti-GAD65 antibodies in the diagnosis of the type of diabetes mellitus

Practical Diabetes International

Volumn 20, Issue 1, 2003, Pages 13-17

  Tankova, Tsvetalina ^a   Dakovska, L ^a   Kirilov, G ^a   Koev, D ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Anti GAD65 antibodies; Insulin secretion; IVGTT; Type 1 diabetes; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY 65; INSULIN; UNCLASSIFIED DRUG;

ADULT; ANALYZER; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNITY; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FEMALE; GLUCOSE TOLERANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRESCRIPTION; PREVALENCE;

EID: 0037285122     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/pdi.416     Document Type: Article

References (27)

1. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Diabetic Med 1998; 15: 539-553.
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
3. Harris M, Zimmet PZ. Classification of diabetes mellitus and other categories of glucose intolerance. In Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus. New York: Wiley 1992; 3-18.
4. Drell DW, Notkins AL. Multiple immunological abnormalities in patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 132-143.
5. Lernmark A, Hagglof B, Freeman Z. A prospective analysis of antibodies reacting with pancreatic islet cells in insulin-dependent diabetic children. Diabetologia 1981; 20: 471-474.
6. Leslie RDG, Atkinson MA, Notkins AL. Autoantigens IA-2 and GAD in type 1 (insulin-dependent) diabetes. Diabetologia 1999; 42: 3-14.
7. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: A precarious balance between insulin action and insulin secretion. In Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus. New York: Wiley 1992, 569-633.
8. Crepaldi G, Del-Prato S. What therapy do our NIDDM patients need? Insulin releasers. Diabetes Res Clin Pract 1995; 28 (Suppl): S159-165.
9. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: A balanced overview. Diabetes Care 1992; 15: 318-368.
10. Porte DJ. Banting lecture 1990. Beta-cells in type 2 diabetes mellitus. Diabetes 1991; 40: 166-180
11. Zimmet PZ, Tuomi T, Mackay IR et al. Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabetic Med 1994; 11: 299-303.
12. Laakso M, Sarlund H, Pyorala K. Clinical characteristics in the discrimination between patients with low or high C-peptide level among middle-aged insulin treated diabetes. Diabetes Res 1987; 4: 95-99.
13. Turner R, Stratton I, Horton V, et al. UKPDS 25: Autoantibodies to islet-cell cytoplam and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997; 350: 1288-1293.
14. Welborn TA, Garcia-Webb P, Bonser AM. Basal C-peptide in the discrimination of type 1 from type 2 diabetes. Diabetes Care 1981; 4: 616-620.
15. Zimmet PZ, Turner R, McCarty D, et al. Crucial points at diagnosis. Type 2 or slow type 1 diabetes. Diabetes Care 1999; 22 (Suppl. 2): B59-64.
16. Grodsky GM. An update on implications of phasic insulin secretion. In: Pickup J, Williams G. eds. Textbook of Diabetes. Oxford: Blackwell 1997; Vol. 1: 421-430.
17. Wallum BJ, Kah SE, McCulloch DK, et al. Insulin secretion in the normal and diabetic human. In Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. Textbook of Diabetes Mellitus. New York: Wiley 1992, 285-301.
18. Warram JH, Sigal RJ, Martin BC, et al. Natural history of impaired glucose tolerance: Follow-up at Joslin Clinic. Diabetic Med 1996; 13 (Suppl 6): S40-45.
19. Gianani R, Pugliese A, Bonner-Weir S, et al. Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type 1 diabetes. Diabetes 1992; 3: 347-353.
20. Bingley PJ, Colman P, Eisenbarth GS, et al. Standardization of IVGTT to predict IDDM. Diabetes Care 1992; 10: 1313-1316.
21. Vardi P, Crisa L, Jackson RA. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 1991; 34: 93-102.
22. Bleich D, Jackson RA, Soeldner JS, et al. Analysis of metabolic progression to type 1 diabetes in ICA+ relatives of ptients with type 1 diabetes. Diabetes Care 1990; 13: 111-119.
23. Tallaride RJ, Murray PB. Manual of Pharmacologic Calculations. Berlin: Springer, 1981.
24. Tiberti C, Falorni A, Torresi P, et al. A new solid-phase radioimmunoassay to detect anti-GAD65 autoantibodies. J Immunol Methods 1997; 207: 107-113.
25. Lohmann T, Kellner K, Seissler S, et al. ICA and GAD- but not IA2-antibody screening is necessary to identify patients with latent autoimmune diabetes in adults. Exp Clin Endocrinol Diab 1999; 107 (Suppl. 1): S53.
26. Von Boehmer H, Sarukhan A. GAD, a single autoantigen for diabetes. Science 1999; 284: 1135-1137.
27. Schmidli RS, DeAizpurua H, Harrison L, et al. Antibodies to glutamic acid decarboxylase in at-risk an clinical insulin-dependent diabetic subjects: Relationship to age, sex and islet cell antibody status, and temporal profile. J Autoimmunity 1994; 7: 55-66.